🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "significant breakthrough" in the fight against drug-resistant strains of the bacteria, according to scientists.

A Worldwide Challenge

Gonorrhoea infections are increasing worldwide, with figures suggesting in excess of 82 million new cases each year. Notably increased rates are seen in Africa and nations within the WHO's designated area, which includes Mongolia and China to New Zealand. In England, cases have reached a record high, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The authorization of new treatments for gonorrhoea is an important and timely step in the context of growing infection rates, increasing antimicrobial resistance and the extremely scarce therapeutic options presently on offer.”

Public health authorities are particularly alarmed about the rise in treatment-resistant strains. The global health body has listed it as a "priority pathogen". Recent surveillance found that the effectiveness of primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Gain Approval

Zoliflodacin, marketed under the name Nuzolvence, was approved by the US FDA in December for treating gonorrhoea. This disease can lead to significant complications, including infertility. Researchers hope that focused deployment of this new drug will help delay the development of resistance.

Gepotidacin, originating from the drugmaker GSK, was also approved in the same week. This drug, which is additionally indicated for urinary tract infections, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin was the result of a unique collaborative effort for medication research. The non-profit organisation GARDP collaborated with the drug firm its industry partner to see it through.

“This approval signifies a major breakthrough in the treatment of highly resistant gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Research Study Results and Global Access

Based on data published in a major medical journal, the new drug eradicated over nine in ten of cases of the STI. This puts it on an similar efficacy with the existing first-line therapy, which combines two antibiotics. The research enrolled hundreds of participants from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, the non-profit has the ability to make available and distribute the drug in many regions with limited resources.

Doctors directly involved have expressed optimism. Having a one-pill regimen such as this is hailed as a "revolutionary step" for public health efforts. This is viewed as crucial to reduce the burden of the infection for people and to stop the proliferation of extremely resistant gonorrhoea around the world.